XML 11 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues        
Total revenues $ 316 $ 468 $ 697 $ 1,016
Cost of revenues 170 124 276 343
Gross profit 146 344 421 673
Operating expenses        
General and administrative 2,589 2,122 5,530 4,322
Research and development 2,954 1,722 5,469 3,941
Total operating expenses 5,543 3,844 10,999 8,263
Loss from operations (5,397) (3,500) (10,578) (7,590)
Other income and (expenses)        
Other income, net 369 87 539 119
Total other income, net 369 87 539 119
Net loss (5,028) (3,413) (10,039) (7,471)
Deemed dividend – warrant inducement offers   (8,501)   (8,501)
Net loss attributable to common stockholders $ (5,028) $ (11,914) $ (10,039) $ (15,972)
Basic net loss per share $ (0.33) $ (1.83) $ (0.67) $ (3.54)
Diluted net loss per share $ (0.33) $ (1.83) $ (0.67) $ (3.54)
Basic weighted average common shares outstanding 15,013,072 6,509,881 14,982,075 4,511,734
Diluted weighted average common shares outstanding 15,013,072 6,509,881 14,982,075 4,511,734
Clinical trial revenue        
Revenues        
Total revenues $ 298 $ 287 $ 557 $ 802
Contract manufacturing lease revenue        
Revenues        
Total revenues 6 159 12 191
Contract manufacturing revenue        
Revenues        
Total revenues $ 12 $ 22 $ 128 $ 23